2019 Form 10-K Annual Report on Form 10-K for the fiscal year ended December 31, 2019 MAA Marketing Authorization Application AbbVie AbbVie Inc. LIBOR London Interbank Offered Rate ACS acute coronary syndrome Lilly Eli Lilly and Company ALL acute lymphoblastic leukemia MCOs Managed Care Organizations Amgen Amgen Inc. mCRPC metastatic castration-resistant prostate cancer Amylin Amylin Pharmaceuticals, Inc. MDL multi-district litigation aNDA abbreviated New Drug Application MDS myelodysplastic syndromes ASEAN Association of Southeast Asian Nations Mead Johnson Mead Johnson Nutrition Company AstraZeneca AstraZeneca PLC Merck Merck & Co., Inc. BCMA B-cell maturation antigen MF myelofibrosis Biogen Biogen, Inc. MSI-H high microsatellite instability BLA Biologics License Application NASH Non alcoholic steatohepatitis CERCLA U.S. Comprehensive Environmental Response, Compensation and Liability Act NAV net asset value Celgene Celgene Corporation Nektar Nektar Therapeutics cGMP current Good Manufacturing Practices NDA New Drug Application CML chronic myeloid leukemia NKT natural killer T CPPIB CPPIB Credit Europe S.A.R.L., a Luxembourg private limited liability company NLRP3 NACHT, LRR and PYD domains-containing protein 3 CRC colorectal cancer Novartis Novartis Pharmaceutical Corporation CytomX CytomX Therapeutics, Inc. NSCLC non-small cell lung cancer dMMR DNA mismatch repair deficient NVAF non-valvular atrial fibrillation DSA Distribution Services Agreement OIG Office of Inspector General of the U.S. Department of Health and Human Services EC European Commission Ono Ono Pharmaceutical Co., Ltd. EGFR estimated glomerular filtration rate OTC Over-the-counter EMA European Medicines Agency Otsuka Otsuka Pharmaceutical Co., Ltd. EPO European Patent Office PBMs Pharmacy Benefit Managers EPS earnings per share PD-1 programmed death receptor-1 ERISA Employee Retirement Income Security Act of 1974 PDMA Prescription Drug Marketing Act ESA erythoropoiesis-stimulating agent Pfizer Pfizer, Inc. ESCC esophageal squamous cell carcinoma PhRMA Code Pharmaceutical Research and Manufacturers of America’s Professional Practices Code EU European Union PRP potentially responsible party FASB Financial Accounting Standards Board PsA psoriatic arthritis FCPA Foreign Corrupt Practices Act R&D research and development FDA U.S. Food and Drug Administration RA rheumatoid arthritis FL follicular lymphoma RCC renal cell carcinoma F-Star F-Star Alpha Ltd. RDP regulatory data protection GAAP U.S. generally accepted accounting principles REMS Risk Evaluation and Mitigation Strategy GBM glioblastoma multiforme Roche Roche Holding AG Gilead Gilead Sciences, Inc. RRMM relapsed/refractory multiple myeloma GILTI global intangible low taxed income RS ring sideroblast GlaxoSmithKline GlaxoSmithKline PLC Sanofi Sanofi S.A. GTN gross-to-net sBLA supplemental Biologics License Application GvHD graft-versus-host disease SCCHN squamous cell carcinoma of the head and neck Halozyme Halozyme Therapeutics, Inc. SCLC small cell lung cancer HCC Hepatocellular carcinoma SEC U.S. Securities and Exchange Commission HIV human immunodeficiency virus STING stimulator of interferon genes HR 3590 The Patient Protection and Affordable Care Act the 2012 Plan The 2012 Stock Award and Incentive Plan ImClone ImClone Systems Incorporated the Act the Tax Cuts and Jobs Act of 2017 IO Immuno-Oncology U.S. United States IPF idiopathic pulmonary fibrosis UK United Kingdom IPRD in-process research and development VAT value added tax JIA Juvenile Idiopathic Arthritis VTE venous thromboembolic LOE loss of exclusivity WTO World Trade Organization 119 Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol-Myers Squibb, BMS, the Company, we, our or us in this 2019 Form 10-K, unless the context otherwise indicates. Throughout this 2019 Form 10-K, we have used terms which are defined below: SUMMARY OF ABBREVIATED TERMS